shivaani kummar ohsu email - sosfoams.com (h.c.), Ph.D., FAACR Director of CEDAR Sadik Esener, Ph.D. Director of precision oncology and SMMART Gordon Mills, M.D.,Ph.D. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Learn more about clinical trials at the Knight Cancer Institute, The 13,000-square-foot early-phase research unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. Together they form a unique fingerprint. The OHSU Knight Cancer Institute has expanded its cancer research and care facilities to include a unit dedicated to serving patients participating in early-phase clinical trials. Shivaani Kummar Dr. Kummar was recently appointed as Division Chief of Hematology and Oncology, and co-Director of the Center for Experimental Therapeutics, at the Oregon Health and Science University in Portland, Oregon. 2001-2022 Oregon Health & Science University. Shivaani Kummar is a Hematology & Medical Oncology Head at Oregon Health & Science University based in Portland, Oregon. Early-phase trials are the first step in testing promising new medications and methods, and can offer patients early access to new and possibly better treatments. Web Browser Accessibility, An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer. Leadership The Center for Experimental Therapeutics is co-led by Sanjay Malhotra, Ph.D., and Shivaani Kummar, M.D. Shivaani Kummar, MBBS, Portland, OR | Oncologist OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Shivaani Kummar, M.D., FACP Expertise Cancer Special focus Medical Oncology and Hematology Email this page Print this page About me Dr. Kummar is a cancer specialist whose focus is to bring new discoveries to the clinic, developing new treatments for cancer. OHSU is an equal opportunity affirmative action institution. Dr. Shivaani Kummar, MD is a medical oncology specialist in Portland, OR. Dr. Shivaani Kummar has primarily specialised in Medical Oncology for over 31 years. And to train and inspire the next generation of doctors and scientists. Stat4Onc Annual Symposium mollie hemingway face shivaani kummar ohsu email. The OHSU Knight Cancer Institute is part of regional, national and international research partnerships, offering patients local access to the latest advances and clinical trials. Shivaani Kummar Professor Professor, Knight Cancer Institute Knight Cancer Translational Oncology Program Email kummar @ ohsu. The new early-phase research unit completes this expansion in the building. DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, S Kummar, R Kinders, ME Gutierrez, L Rubinstein, RE Parchment, Journal of clinical oncology 27 (16), 2705. DR. SHIVAANI KUMMAR NPI 1053612341 - NPI Profile Knight Cancer Institute Leaders | Knight Cancer Institute | OHSU (h.c.), Ph.D., FAACR. Shivaani Kummar. Shivaani Kummar M.D., FACP | Health care provider | OHSU The provider is located at 3181 Sw Sam Jackson Park Rd Portland, Or 97239 and the phone number is (503) 314-7168 Which is Dr. Shivaani Kummar specialty? shivaani kummar ohsu email. Dr. Shivaani Kummar is an oncologist practicing in Bethesda, MD. & Kummar, S. Research output: Contribution to journal Comment/debate peer-review, Research output: Contribution to journal Review article peer-review, Research output: Contribution to journal Article peer-review, Powered by Pure, Scopus & Elsevier Fingerprint Engine 2023 Elsevier B.V, We use cookies to help provide and enhance our service and tailor content. Nature reviews Drug discovery 9 (11), 843-856. Faculty and staff recruitment information. Want to join the faculty at the Knight Cancer Institute? Most recently, he was the director for Stanford SRI Drug Discovery and Development Program, and he trained with Nobel laureate Herb Brown at Purdue University. Combination therapy with pazopanib and tivantinib modulates VEGF and c At the end of the day, we need to develop better treatment for cancer patients and the only way to build that is through collaboration within OHSU and with other academic centers, biotech and pharma companies., Team science can be a buzz word. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. Keep me signed in. For help with all referral needs and questions, visit Referring Physicians. Hamburger Menu x Home The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU. However, high costs, long development t Today is a global celebration of giving an opportunity to support the causes that matter the most to you. 23 () 'Oregon Health & Science University Knight Cancer Institute (OHSU)' BAL0891 1 . We are proud to be able to offer our patients access to the most advanced cancer therapies available, said Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institutes Center for Experimental Therapeutics. Support the Abortion Care and Training Fund. You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number - 503-314-7168). OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. The patient ratings score is an average of all responses to the question "How likely would you be to recommend this provider to your family and friends (on a scale of 0 to 10)" on our nationally-recognized NRC patient surveys. Together their goal is to find a cure for cancer. Accueil; Solution; Tarif; PRO; Mon compte; France; Accueil; Solution Sanjay Malhotra, Ph.D. Shivaani Kummar, M.D., FACP Try restaurant style recipes at home. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Very few institutions do it well, but OHSU truly gets it, Kummar says. The purpose of the study is to learn more about the study drug, VIP152, in combination with pembrolizumab in people with advanced or . Shivaani Kummar: STUDY00021194: A phase 1 study of SGN-CD228A in select advanced solid tumors: . , 'Bal0891' 1 Its staff of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. In her most recent role at Stanford University, Kummar held a number of titles, including: professor of medicine and radiology; associate division chief for academic affairs; director, phase I clinical research program; and co-director of the Translational Oncology Program. Shivaani Kummar - .. - Oregon Health & Science University - ZoomInfo Administrative Coordinator, Margaret Rogers Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid When were developing new treatments for cancer, we are often trying to identify what makes the cancer different from normal cells or why currently used drugs are not working as well as we would like them to. A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, Clinical cancer research 18 (8), 2344-2351. She co-leads a team of 90 faculty members and along with her husband, Sanjay Malhotra, PhD, is focused on discovering new therapies for cancer and giving more people access to safe, experimental cancer treatments. Dr. Jody Kujovich, MD - Portland, OR | Oncology - Doximity In 2021, we held our 4th Stat4Onc Symposium virtually by Stanford University. She also leads the division of hematology & medical oncology in the OHSU School of Medicine. Read More Contact Shivaani Kummar's Phone Number and Email Last Update 11/29/2022 2:55 AM Email s***@ohsu.edu Engage via Email Contact Number (***) ***-**** Engage via Phone Mobile Number (***) ***-**** Engage via Mobile HQ Phone Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Neoadjuvant nivolumab shows long-term benefit in NSCLC Of that, $160 million was used for the Knight Cancer Research Building, which opened in 2018, and $40 million was used to build expanded capacity for clinical trial care in CHH2, which opened in 2019. Uncategorized . Together they have built a strong record of discovery, innovation and care. Select a country/territory to view shared publications and projects. 2001-2022 Oregon Health & Science University. Response to treatment was evaluated at cycle 1 and every six cycles, that is, 18 weeks, by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. Lisa M. Coussens, M.D. Web Browser Accessibility, New early-phase clinical trial unit in the Center for Health and Healing Building 2 on South Waterfront centralizes care for cancer patients, provides more research opportunities, OHSU expands capacity for cancer clinical trials, OHSU Knight Cancer Institute: Understanding Cancer Clinical Trials, Expanding access to experimental cancer treatments in Oregon: Q&A with Shivaani Kummar, Severe respiratory illness season means boom times for OHSU virtual immediate care, OHSU leading effort to make cancer trials more inclusive, OHSU Child Life Specialist provides life-changing care to young patient living with chronic spinal condition, Making Hepatitis C care easier when treatment seems impossible. Within our Center for Experimental Therapeutics, Knight Cancer Institute, we have multiple ongoing projects trying to identify new ways to target cancer. OHSU Foundation P.O. what was bolivar's ultimate goal? Across OHSU, doctors and researchers are reimagining early disease detection. OHSU expands capacity for cancer clinical trials | OHSU News Sort. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. All these new agents have shown promising anticancer activity in laboratory testing and are now being evaluated in patients. shivaani kummar ohsu email - howfenalcooksthat.com Program Guide - ASCO Meeting Program Guide - American Society of [] , 'Nm301' Als 2001-2022 Oregon Health & Science University. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight. Under his leadership, the Knight Cancer Institute is actively engaged in doing so., Brian Druker, M.D., Knight Cancer Institute director, JELD-WEN Chair of Leukemia Research; investigator, Howard Hughes Medical Institute. Knight Cancer Institute | OHSU Knight Cancer Institute | OHSU Administrative Coordinator, Ingrid Studebaker This new unit allows us to centralize everything in a setting designed for a patients convenience and comfort, said Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute. Dr. Shivaani Kummar - Medical Oncology, Portland OR Email: trials@ohsu.edu Call: 503-494-1080 Oregon Health & Science University. Dr. Kummar specializes in the care and treatment of patients with cancer. SHIVAANI KUMMAR, Medical Oncology PORTLAND, OR - NPI 1053612341 Professor of Medicine, OHSU. February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC massachusetts vs washington state. Sort by citations Sort by year Sort by title. Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer . OHSU HOSPITAL AND CLINICS: 380009: Provider Business Practice Location Address Details: Address: 3181 Sw Sam Jackson Park Rd, City: Portland . Administrative Coordinator, Denise Hopkins Yourinsurancecompany will also be able to inform you of any copayments, coinsurance, or deductibles that will be your responsibility. (OHSU/Kristyna Wentz-Graff). By continuing you agree to the use of cookies. Cited by. BYLINE. 1 - 20 out of 67 Results for "Shivaani Kummar" 67 Results Select All . billing andinsurancesection of our site, Medical Oncology and Hematology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, American Board of Internal Medicine Board Certified in Internal Medicine, 1995-2005, Board Recertified in Internal Medicine, 2005-2015, Board Certified in Medical Oncology, 1998-2008, Board Recertified in Medical Oncology, 2008-2018; 2018-2028 Board Certified in Hematology, 2002-2012, Member, American Society of Clinical Oncology, Member, American Association for Cancer Research. Her husband is a synthetic medicinal chemist who leads the Center for Experimental Therapeutics dedicated to discovery new cancer treatments. (h.c.), Ph.D., FAACR. Notice of Privacy Practices Faculty Spotlight - Shivaani Kummar, MD, FACP | Department of Medicine February 17, 2023. By Shivaani Kummar, Antoine Italiano, Marcia S Brose, Josh Carlson | American Journal of Managed Care ABSTRACTThe tropomyosin receptor kinase (TRK) family of proteins is encoded by neurotrophic tyrosine receptor kinase (NTRK) genes and has a role in the development and normal functioning of the nervous system. Division of Hematology and Medical Oncology Faculty and Staff - OHSU Each faculty member comes with a unique background, which often propels him or her into medicine and a particular . (Getty Images), Communications Manager, OHSU Knight Cancer Institute, Husband-wife team from Stanford University tapped to lead two cancer programs at OHSU, OHSU leading effort to make cancer trials more inclusive, Making Hepatitis C care easier when treatment seems impossible, Pill for skin disease also curbs excessive drinking, OHSU clinical trial tests exercise for multiple sclerosis treatment. 2001-2022 Oregon Health & Science University. Shivaani Kummar Stanford University Medical Center - PMWC Precision Medicine World Conference Speaker Profile M.D., Professor of Medicine and Radiology, Stanford University; Director, Phase I Clinical Research Program-Medical Oncology; Director, Translational Oncology Program At Stanford Shivaani Kummar Biography S Kummar, R Kinders, L Rubinstein, RE Parchment, AJ Murgo, J Collins, Journal of Soil and Water Conservation 53 (3), 230-240. People | OHSU . Shivaani Kummar (OHSU) kummar@ohsu.edu Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. It is a privilege to be able to work in this field. Password. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. You may also qualify for Phase 1 Program trials. Shivaani Kummar (Principal Investigator, PI), OHSU Mary Crowley Cancer Research, Montefiore Medical Center 4 1 . Recent external collaboration on country/territory level. Before scheduling your appointment, we recommend you contact yourinsurancecompany to verify that the OHSU Health location or provider you plan to visit is included in your network. Expanding scientific knowledge is a key mission of OHSU, Oregons only academic health center. To find better ways to treat patients. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. Dr. Notice of Privacy Practices Trisha Silbernagel, RN, BSN, early-phase clinical trial unit manager, checks equipment on Aug. 23, 2021. Stat4Onc Annual Symposium (2022) - University Of Connecticut In Brief. Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. OHSU is an equal opportunity affirmative action institution. As an oncologist, Dr. Kummar manages and oversees the treatment of a cancer patient after he or she has been diagnosed with the disease. Shivaani Kummar, M.D., FACP, is head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics. Clinical trials are research studies that test how well new medicines or treatments work in people. shivaani kummar ohsu email Division head of medical oncology Shivaani Kummar, M.D., FACP Accepting new patients Division head of radiation medicine Arthur Y. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. S Kummar, ME Gutierrez, ER Gardner, X Chen, WD Figg, M Zajac-Kaye, European journal of cancer 46 (2), 340-347, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasPhase I Trial of ABT-888 with Topotecan, Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Compressing drug development timelines in oncology using phase'0'trials, Wee1 kinase as a target for cancer therapy, Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain, A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas, SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudySD-101 Combined with Pembrolizumab in Advanced Melanoma, Cediranib for metastatic alveolar soft part sarcoma, Primary non-Hodgkin's lymphoma of the liver, Drug development in oncology: classical cytotoxics and molecularly targeted agents, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsPhase I Study of Olaparib with Cisplatin and Gemcitabine, Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerAdenosine 2A Receptor Blockade as a Cancer Immunotherapy, Advances in using PARP inhibitors to treat cancer, Clinicopathologic Features of NonSmall-Cell Lung Cancer Harboring an, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies, Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.